post result beat consensu sale ep estim compani show
organ sale growth guidanc rang also north
organ rate shown rais ep forecast
despit recent usd strengthen reiter outperform
multifacet strength fuel confid outlook
revenu total quarter vs street expect revenu
improv organ basi exceed top compani
guidanc rang well organ sale growth demonstr return
stellar organ sale growth result shown impress
manag averag organ sale growth past four quarter
nutrit sale surpass street consensu repres
organ growth last quarter fuel solid intern show
diagnost sale fell modestli short street forecast though
organ growth vs last quarter includ intern growth
core laboratori busi help continu roll-out alin europ
anticip growth remain solid alin launch get
underway earnest next year diagnost sale total
reiter belief rapid diagnost contribut slightli year
epd sale total essenti line consensu
organ sale growth epd nearli doubl growth seen
compar low-teen growth rate shown epd busi grow
faster sever prioriti countri india china medic devic sale exceed
consensu forecast vs organ par
recent strength divis medic devic franchis benefit impress
perform electrophysiolog structur heart
diabet sale total compar consensu forecast
repres organ growth mark third consecut
quarter sale growth growth streak that made possibl freestyl
libr libr user global last quarter
track line per month addit manag previous outlin
obvious confid reach goal patient year-end
ahead schedul equal confid compani reach top end
 sale guidanc libr well indic global mix
two-third type patient one-third type user believ captur util
devic patient type libr commerci momentum continu
devic upcom develop mileston pediatr label
next-gener system part collabor bigfoot medic
adjust gross margin match street project well
compani guidanc gross margin around adjust invest
sale adjust sg expens sale lastli adjust ep
came two cent better street project two cent
midpoint abt guidanc rang
pleas see page report import disclosur
spin-out proprietari pharma new redux pre-humira
larg diversifi medic product compani competit global franchis
nutrit diagnost medic devic intern brand gener pharmaceut
post-spin ad st jude medic aler busi divest
advanc medic optic unit next five year believ combin abt/stj/
alr busi pois deliv revenu growth ep growth low mid-
teen make standout perform compar medic devic peer believ
may upsid estim potenti out-performance busi unit
better-than-expect contribut stj pipelin product success business-
develop initi blend valuat analysi dcf sum-of-the-part price-to-earnings
support outperform rate expect share outperform market
increas market adopt mitraclip
alin roll
gross oper margin expans
next five year
 enhanc product
acceler diagnost unit
persist emerg market headwind
nutrit
stronger stj synergi captur alr
acceler recoveri intern
hsd revenu mid-dd ep growth
franchis four major health care segment one diversifi
large-cap medic devic compani world offer lead product
nutrit diagnost medic devic establish brand gener pharmaceut
approxim compani revenu gener unit state
anoth come western europ canada japan australia remain
emerg market includ india china russia brazil januari
complet separ proprietari research-bas pharmaceut busi
oper independ large-cap pharmaceut compani
guidanc target appear achiev us
along result increas full-year ep guidanc
midpoint vs prior guidanc midpoint street
consensu compani increas full-year organ sale growth forecast
rang previous anticip favor impact
currenc around bp bp slightli
guidanc manag provid april time result mention
forecast legaci aler busi littl sale unchang
call busi segment increas full-year sale growth project
nutrit msd lsd previous medic devic hsd msd/hsd
previous move compani margin target chang
slightli sg slightli vs slightli previous
mean abt gross margin assumpt unchang somewhat
respect
compani anticip msd/hsd organ sale growth rate currenc
neg impact approxim rapid diagnost forecast
contribut roughli sale busi expect organ sale growth
msd/hsd epd msd nutrit msd/hsd diagnost hsd medic devic
dd growth sever area divis compani anticip adjust gross
margin around sale adjust adjust sg expens
around lastli manag issu ep guidanc
bracket street forecast view target achiev base abt
challeng comp ground exit long posit
think abt result frame bull case stock solid diversifi sale growth
consist earn upsid regard sustain recent sale growth rate
manag stress confid nutrit busi diagnost thank
part roll-out alin europ latter compani also indic
larg work temporari disrupt experienc recent russia epd
busi return growth region neuromodul call
slowdown self-inflict didnt expand sale forc suffici match
strong sale growth experienc recent quarter howev manag believ
setback temporari voic confid return market growth
think sale growth sustain concern also lessen libr devic
attain billion-dollar world-wide run rate year margin perspect much
underli oper margin progress mask three headwind aler
bp invest libr alin bp currenc bp even
headwind think could show bp year-over-year oper margin
expans look ahead forecast adjust oper margin
bp year year increas view feasibl headwind subsid
increas price
share trade roughli time forward earn close averag
forward price-to-earnings multipl compani large-cap peer group medic devic compani
base abt above-averag sale earn growth rate rel peer
believ compani share warrant premium group therefor use
forward price-to-earnings multipl valuat rais price target
revis target incorpor ep estim also support
discount cash flow sum-of-the-part analys expect stock momentum
continu remain outperform
compani report thomson eikon cowen compani
consensu chg establish lab molecular poc medic cv rhythm manag heart structur diabet good gross gross maugin oper interest interest net interest expens currenc hedg expens net expens pre-tax incom tax incom tax net incom continu restructur non-recur charg net incom continu oper dilut share compani report cowen compani estimatesour estimatesactu cowen
compani report thomson eikon cowen compani
consensu chg pharma nutrit ww nutrit ww nutrit ww cardiovascular neuromodul ww rhythm manag ww electrophysiolog ww heart failur ww vascular ww structur heart ww neuromodul ww ww diagnost ww diagnost ww diagnost ww actualsour estim cowen
compani report thomson eikon cowen compani
good gross gross margin oper interest interest net interest expens currenc hedg expens net expens pre-tax incom tax incom tax net incom continu restructur non-recur charg net incom continu oper restructur non-recur charg dilut share analysisgross end decemb end decemb end decemb cowen
compani report thomson eikon cowen compani
laboratori diagnost laboratori diagnost molecular diagnost point diagnost point diabet revenu rhythm manag heart failur rhythm manag heart cardiovascular structur heart cardiovascular structur revenu end decemb end decemb end decemb cowen
compani report thomson eikon cowen compani
adjust good adjust gross adjust gross oper incom oper incom interest expens interest net interest expens currenc hedg loss expens net expens pre-tax incom incom tax incom tax net incom adj net incom oper net incom oper ep continu oper ep discontinu oper changeadjust ep oper includ disc ep oper share analysisgross incom -oper cowen
compani report thomson eikon cowen compani
 exclud ww sale exclud pharma exclud exclud ww sale exclud devic tradit exclud ww tradit ww sale exclud atrial fibril exclud ww atrial ww sale exclud heart failur exclud ww heart ww sale exclud rhythm manag heart failur exclud ww rhythm manag heart ww sale exclud vascular exclud ww ww sale exclud structur heart exclud ww ww sale exclud cardiovascular structur heart exclud ww ww sale exclud neuromodul exclud ww ww sale exclud neuromodul exclud ww stj ww sale exclud diabet exclud ww diabet ww sale exclud revenu exclud ww ww sale exclud total revenu exclud ww sale exclud total revenu pro-forma stj alr exclud ww sale exclud cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
competit dynam global potenti regulatori delay potenti delay
time product launch emerg develop market econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend share repurchas fluctuat foreign exchang rate
risk includ stj alr integr global competit pressur adult
pediatr nutrit busi price pressur procedur volum pressur
stent busi vascular product regulatori time approv mitraclip
 risk time regulatori approv meet demand
hundr product launch emerg market establish pharmaceut
busi meet growth target develop emerg market
meet target margin improv four major segment
